FIELD: biotechnology.
SUBSTANCE: invention relates to the methods of selecting and using known drugs and pharmaceutical compounds that cause mitochondrial dysfunction in macrophages for antitumor therapy. The claimed invention provides the possibility of using drugs and pharmacological compounds known as such that affect macrophages by changing their mitochondrial functions, namely, shifting mitochondrial metabolism from oxidative phosphorylation, characteristic of M2 type macrophages, to the glycolytic type, characteristic of M1 type macrophages, for treatment of oncological diseases.
EFFECT: invention is promising for the treatment of cancer, and can also be used in the future to prevent the occurrence of cancer.
1 cl, 14 dwg, 2 tbl, 7 ex
| Title | Year | Author | Number |
|---|---|---|---|
| APPLICATION OF MEMBRANE VESICLES OF MULTIPOTENT STROMAL CELLS INDUCED BY B CYTOCHALASIN, FOR RESTORATION AND INCREASE OF MITOCHONDRIAL FUNCTION | 2019 |
|
RU2727540C1 |
| METHOD FOR OBTAINING PRIMARY MACROPHAGE LINES WITH PRO-INFLAMMATORY PROPERTIES | 2022 |
|
RU2792602C1 |
| METHOD OF SUBCUTANEOUS TRANSPLANT GROWTH INHIBITION OF EXPERIMENTAL HUMAN GLIOBLASTOMA U-87, TRANSPLANTED TO IMMUNODEFICIENT MICE Nu/J | 2019 |
|
RU2717218C1 |
| METHOD FOR IDENTIFYING FUNCTIONAL M1 AND M2 PHENOTYPE OF HUMAN MACROPHAGES GENERATED IN VITRO FROM BLOOD MONOCYTES | 2019 |
|
RU2717024C1 |
| METHOD FOR TUMOUR GROWTH INHIBITION IN EXPERIMENT | 2015 |
|
RU2599438C1 |
| METHOD OF TUMOUR GROWTH INHIBITION BASED ON IN VITRO REPROGRAMMING MACROPHAGES ON M1 PHENOTYPE WITH HIGH ABILITY OF NITRIC OXIDE PRODUCTION IN EXPERIMENT | 2015 |
|
RU2599545C1 |
| USE OF GRAPHENE OXIDE TO ACTIVATE PHAGOCYTIC FUNCTION OF MACROPHAGES | 2022 |
|
RU2809372C1 |
| COMBINATION OF SIROSINGOPIN AND MITOCHONDRIAL INHIBITORS FOR TREATMENT OF CANCER AND FOR IMMUNOSUPPRESSION | 2012 |
|
RU2602937C2 |
| METHOD OF SUPPRESSION OF INFLAMMATORY RESPONSE IN PERIODONTAL TISSUES IN AN EXPERIMENT | 2017 |
|
RU2677642C1 |
| METHOD FOR SCREENING ANTITUMOUR PREPARATIONS IN VITRO ON A MULTICOMPONENT CELL TEST SYSTEM | 2018 |
|
RU2695568C1 |
